Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 2,498 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| SAB Biotherapeutics Inc | SABSW | NASDAQ | Equity Warrant |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.0001 | 0.28% | 0.0362 | 15:02:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0363 | 0.0362 | 0.0363 | 0.0362 | 0.0361 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
|---|---|---|---|---|
| 10 | 2,498 | 0.0362999 | 91 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:00 | 99 | 0.0363 | USD |
SAB Biotherapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.89M | 52.32M | - | 2.24M | -42.19M | -0.81 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News SAB Biotherapeutics
| Date | Time | Source | Heading |
|---|---|---|---|
| 2/05/2025 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/28/2025 | 06:11 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/05/2024 | 15:41 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 9/09/2024 | 07:21 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/30/2024 | 16:15 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 5/21/2024 | 06:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/20/2024 | 16:45 | GlobeNewswire Inc. | SAB Biotherapeutics Announces Q1 2024 Financial Results and.. |
| 5/20/2024 | 15:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/06/2024 | 06:15 | GlobeNewswire Inc. | SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of.. |
| 4/16/2024 | 06:15 | GlobeNewswire Inc. | SAB Biotherapeutics Provides SAB-142 Trial Update |
| 4/08/2024 | 06:15 | GlobeNewswire Inc. | SAB Biotherapeutics to Present at INNODIA Annual Meeting |
| 4/04/2024 | 06:15 | GlobeNewswire Inc. | SAB Biotherapeutics to Present at the Needham Virtual.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
SABSW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| SAB BIO is a clinical-stage biopharmaceutical company working to treat and prevent immune and autoimmune disorders. Founded in 2014 and traded on NASDAQ (SABS) since 2021, SAB BIO's innovative genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma. The science behind the platform originated in 1998, and the company began its first clinical trials in 2017. To date, SAB BIO has conducted seven clinical trials that have dosed 700 individuals across multiple therapeutic areas. The safety and immunogenicity database for these trials shows zero patients with serum sickness or neutralizing anti-drug antibodies, which suggests an improved safety profile over other therapies. |
NASDAQ:SABSW -
What is the current SAB Biotherapeutics Inc share price?
The current share price of SAB Biotherapeutics Inc is US$ 0.0362
How many SAB Biotherapeutics Inc shares are in issue?
SAB Biotherapeutics Inc has 52,319,000 shares in issue
What is the market cap of SAB Biotherapeutics Inc?
The market capitalisation of SAB Biotherapeutics Inc is USD 1.89M
What is the 1 year trading range for SAB Biotherapeutics Inc share price?
SAB Biotherapeutics Inc has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of SAB Biotherapeutics Inc?
The price to earnings ratio of SAB Biotherapeutics Inc is -2.38
What is the cash to sales ratio of SAB Biotherapeutics Inc?
The cash to sales ratio of SAB Biotherapeutics Inc is 44.86
What is the reporting currency for SAB Biotherapeutics Inc?
SAB Biotherapeutics Inc reports financial results in USD
What is the latest annual turnover for SAB Biotherapeutics Inc?
The latest annual turnover of SAB Biotherapeutics Inc is USD 2.24M
What is the latest annual profit for SAB Biotherapeutics Inc?
The latest annual profit of SAB Biotherapeutics Inc is USD -42.19M
What is the registered address of SAB Biotherapeutics Inc?
The registered address for SAB Biotherapeutics Inc is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the SAB Biotherapeutics Inc website address?
The website address for SAB Biotherapeutics Inc is www.sab.bio
Which industry sector does SAB Biotherapeutics Inc operate in?
SAB Biotherapeutics Inc operates in the BLANK CHECKS sector
